-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s Azithromycin Tablets (0.25g) Have Been Approved.
Category:
Time：2022-11-15
Recently, Shijiazhuang Fourth Pharmaceutical Group has once again achieved a significant milestone in scientific research and development: its Class 4 chemical drug, azithromycin tablets (0.25g), has been granted a drug registration certificate by the National Medical Products Administration and is considered to have passed the evaluation of consistency in quality and efficacy with generic drugs.
Recently, Shijiazhuang Fourth Pharmaceutical Group has once again achieved a significant milestone in scientific research and development: its Class 4 chemical drug, azithromycin tablets (0.25g), has been granted a drug registration certificate by the National Medical Products Administration and is deemed to have passed the evaluation of quality and efficacy consistency for generic drugs.
It is reported that azithromycin is a second-generation macrolide antibiotic, primarily used to treat lower respiratory tract infections such as bronchitis and pneumonia caused by susceptible bacteria, as well as skin and soft-tissue infections, acute otitis media, sinusitis, pharyngitis, and tonsillitis—upper respiratory tract infections.
In September of this year, the group’s azithromycin dry suspension was the first domestically approved by a pharmaceutical company and was deemed to have passed the consistency evaluation. The recent approval of azithromycin tablets (0.25g) will strongly promote product serialization and diversification, optimize the company’s product portfolio, and boost its high-quality development. Since the beginning of this year, Shijiazhuang Fourth Pharmaceutical Group has obtained a total of 36 product approvals, including 27 formulation approvals.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license